Diffusion Board Urges Stockholders To Vote "FOR" Each Of Its Six Nominees For Director

By RTTNews Staff Writer ✉ | Published: 12/5/2022 7:09 AM ET

Biopharmaceutical company Diffusion Pharmaceuticals Inc. (DFFN) said Monday in a letter to its stockholders that the Company's board of directors continue to take steps to unlock stockholder value through a strategic review process.

The letter also summarizes the value-destructive acquisition offer presented by LifeSci Capital on behalf of a purported client, the dismal track record of LifeSci Capital and its many affiliates in the biopharmaceutical space.

The letter also states that Diffusion's board of directors urges stockholders to vote "FOR" each of its six nominees for director on your WHITE proxy card.

It also noted LifeSci-affiliated funds' recent nomination of an unqualified dissident slate of nominees for election as directors at the Company's 2022 Annual Meeting of Stockholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In March 2023

Biotech Stocks Facing FDA Decision In February 2023

Biotech stocks Facing FDA Decision in January 2023

Editors Pick

United Airlines, Archer To Launch First Air Taxi Route In Chicago

United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route.

Aunt Millie's Our Family White Hot Dog Buns Recalled

Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie.

Ascend Labs Recalls Oral Anticoagulant Dabigatran Etexilate Capsules

Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.

Latest Updates on COVID-19

34% Fall In US Covid Cases, 38% Fall In Deaths In Last 2 Weeks

Biden Signs Covid Origins Bill Into Law

FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5

Covid Cases, Hospitalizations Fall Nationwide In Last 2 Weeks

FDA Authorizes First At-Home Test To Detect Flu And COVID-19

COVID-19: Drugs in Development

Follow RTT

Most Read
Most Emailed

Diffusion Board Urges Stockholders To Vote "FOR" Each Of Its Six Nominees For Director

Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

Accenture Sees Higher Q3 Revenues; Cuts FY23 Earnings, Sales Growth View - Update

FDA Clears Eat Just's Good Meat Cultivated Chicken

Pearson In Deal To Sell Pearson Online Learning Services To Regent

Foot Locker Q4 Profit Down, Warns On FY23; To Close Hong Kong Operations

Zai Lab Partner Karuna's Phase 3 Trial Of KarXT In Schizophrenia Meets Primary Endpoint

Knight-Swift To Acquire U.S. Xpress Enterprises For Enterprise Value Of $808 Mln

PDD Holdings Q4 Profit Rises 43%

Sandoz Gets FDA Approval For Biosimilar Hyrimoz High-concentration Formulation

89bio: Phase 2b ENLIVEN Trial Of Pegozafermin In Patients With NASH Meets Primary Goals

Ascend Labs Recalls Oral Anticoagulant Dabigatran Etexilate Capsules

FDA Bans 2 Vuse Solo Menthol E-cigarette Products

Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

Playtech FY22 Profit Down, Revenues Rise; Says Strong Start To FY23

Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS

ITT Ink 10-Year Strategic Agreement With Continental To Supply Aftermarket Brake Pads

Heidelberg Materials Lifts Annual Dividend

Kite Reports Primary Overall Survival Analysis Results Of Phase 3 ZUMA-7 Study

Knight-Swift To Acquire U.S. Xpress Enterprises For Enterprise Value Of $808 Mln

Coya Therapeutics In Deal With Dr. Reddy's To License Proposed Biosimilar Abatacept For Coya 302

Canadian Solar Inc. Q4 Income Rises

Trupanion CFO Drew Wolff To Step Down Effective June 1

HORNBACH Group FY Adj. EBIT To Decrease By Approx. 20%; Group Sales Up 6.6%

Accenture Sees Higher Q3 Revenues; Cuts FY23 Earnings, Sales Growth View - Update